Drugs.com - Clinical Trials

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28 2025 -- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics today announced that the pivotal phase III PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including...

Jun 3, 2025 - 05:35
 0
PIVOT-PO Phase III Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 28 2025 -- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics today announced that the pivotal phase III PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including...
Read More

Tags:

Previous Article

Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of...

Next Article

FDA Approves Khindivi (hydrocortisone) Oral Solution for Pediatric Patients with...

Related Posts

GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis

GLISTEN Phase III Trial Results Show Linerixibat Signif...

May 12, 2025  0

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

May 12, 2025  0

Infant with Carbamoyl Phosphate Synthetase 1 (CPS1) Deficiency First to Successfully Receive Personalized Gene Therapy Treatment

Infant with Carbamoyl Phosphate Synthetase 1 (CPS1) Def...

May 20, 2025  0